NUVATION BIO NUVB 深 沪
等待开盘 09-18 09:30:00 美东时间
6.07
+0.290
+5.02%
华盛通- 最 高6.16
- 今 开5.96
- 成交量 573.88万股
- 最 低 5.92
- 昨 收 5.78
- 总市值 21.31亿
- 52周最高 9.75
- 市盈率 静 --
- 换手率 1.63%
- 52周最低 3.15
- 委 比 0.00%
- 总股本 3.51亿
- 历史最高 15.23
- 量 比 0.89
- 振 幅 4.15%
- 历史最低 0.95
- 每 手 1
- 风险率 1.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Nuvation Bio Stock Gaining Thursday?
On Thursday, the U.S. Food and Drug Administration (FDA) approved Nuvation Bio Inc.’s (NYSE:NUVB) supplemental New Drug Application (sNDA) regarding its oncology drug IBTROZI (taletrectinib). Following the announcement, the stock gained over 6%. The approval comes four months ahead of the PDUFA date...
今天 00:46
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IBTROZI In Both TKI- Naïve And TKI-Pretreated Patients With Advanced ROS1+ NSCLC
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroups Among patients who received IBTROZI after prior chemotherapy, response rates remained con...
09-15 20:06
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13
JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweight rating and announces Price Target of $13.
08-18 20:24
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $20
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $19 to $20.
08-08 03:58
财报速睇 | NUVATION BIO 2026财年Q2营收0.32亿美元，同比增长555.7%；归母净利润亏损0.63亿美元，同比亏损扩大6.5%
华盛资讯8月6日讯，NUVATION BIO公布2026财年Q2业绩，公司Q2营收0.32亿美元，同比增长555.7%，归母净利润亏损0.63亿美元，同比亏损扩大6.5%。
08-06 19:54
Nuvation Bio Q2 EPS $(0.18) Beats $(0.19) Estimate, Sales $31.687M Beat $27.505M Estimate
Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 5.88 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $31.687 million which...
08-06 18:58
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
